| Total group (n = 90) | Additional treatment (n = 21) | No additional treatment (n = 69) | Additional treatment vs No additional treatment P value |
---|---|---|---|---|
Age, mean (SD) | 53.6 (12.2) | 52.6 (10.8) | 53.9 (12.7) | 0.270 |
Male/female, n/n | 53/37 | 15/6 | 38/31 | 0.167 |
Disease duration diagnosis mean, (SD) | 11.0 (9.2) | 10.8 (8.6) | 11.2 (9.4) | 0.837 |
On treatment > 6 months, % | 92 | 90 | 93 | 0.057 |
Swollen joints | 0 (-0–1) | 0 (0–1.5) | 0 (0–1) | 0.359 |
SJC of 0, n (%) | 63 (70) | 13 (62) | 50 (72) | Â |
SJC of 1, n (%) | 8 (9) | 3 (14) | 5 (7) | |
SJC of 2, n (%) | 5 (6) | 2 (10) | 3 (4) | |
SJC of ≥3, n (%) | 14 (16) | 3 (14) | 11 (16) | |
Tender joints | 1 (0–3) | 1 (0–2) | 1 (0–3) | 0.923 |
TJC of 0, n (%) | 36 (40) | 7 (33) | 29 (42) | |
TJC of 1, n (%) | 16 (18) | 8 (38) | 8 (12) | |
TJC of 2, n (%) | 12 (13) | 2 (10) | 10 (15) | |
TJC of ≥3, n (%) | 25 (27) | 4 (20) | 21 (30) | |
Number of dactylitic digits | 0 (0–0) | 0 (0–0) | 0 (0–0) | 0.310 |
Dactylitic digits ≥1, n (%) | 8 (9) | 3 (14) | 5 (8) |  |
Number of enthesitis points | 0 (0–0) | 0 (0–0) | 0 (0–0) | 0.384 |
Enthesitis points ≥1, n (%) | 16 (18) | 5 (24) | 11 (16) | |
VAS physician skin severity | 1 (1–3) | 2 (1–3.5) | 1 (1–2) | 0.478 |
VAS physician overall disease activity | 2 (1–4) | 3 (2–5) | 2 (1–3) | 0.007 |
VAS patient global disease activity | 5 (2–7) | 6 (3–7) | 5 (2–7) | 0.157 |
VAS pt pain | 5 (2–7) | 6 (3–7) | 4 (2–7) | 0.225 |
BASDAI | 4.1 (2.5–5.9) | 4.2 (2.7–5.8) | 3.7 (2.5–5.9) | 0.907 |
cDAPSA remission, n (%) | 9 (10) | 1 (5) | 8 (12) | 0.594 |
cDAPSA low disease activity, n (%) | 34 (38) | 7 (33) | 27 (39) | Â |
cDAPSA moderate disease activity, n (%) | 35 (39) | 11 (52) | 23 (33) | Â |
cDAPSA high disease activity, n (%) | 6 (7) | 2 (10) | 4 (6) | Â |
cDAPSA missing, n (%) | 6 (7) | 0 | 6 (9) | Â |